Opus Genetics (IRD) Receivables - Net (2012 - 2026)
Opus Genetics (IRD) reported Receivables - Net of $1.7 million for Q1 2026, down 43.8% year-over-year from $3.1 million in Q1 2025, and down 13.23% on a QoQ basis from $2.0 million in Q4 2025.
Opus Genetics (IRD) has 10 years of Receivables - Net data on file, last reported at $1.7 million in Q1 2026.
- Quarterly Receivables - Net fell 43.8% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 43.8% YoY) and the FY2025 annual result came in at $2.0 million, down 44.01% from the prior year.
- Receivables - Net eased to $1.7 million in Q1 2026 per IRD's latest filing, from $2.0 million in the prior quarter.
- Across five years, Receivables - Net topped out at $10.1 million in Q3 2023 and bottomed at $135000.0 in Q2 2023.
- The 5-year median for Receivables - Net is $2.0 million (2024), against an average of $2.7 million.
- Peak annual rise in Receivables - Net reached 905.93% in 2024, while the deepest fall reached 81.67% in 2024.
- Tracing IRD's Receivables - Net over 5 years: stood at $1.3 million in 2022, then slipped by 28.66% to $926000.0 in 2023, then jumped by 284.77% to $3.6 million in 2024, then slumped by 44.01% to $2.0 million in 2025, then declined by 13.23% to $1.7 million in 2026.
- Per Business Quant, the three latest IRD Receivables - Net figures stand at $1.7 million (Q1 2026), $2.0 million (Q4 2025), and $2.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.73 Mn |
| Mar 31, 2026 | 1.73 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.92 Mn |
| Sep 30, 2025 | 2.92 Mn |
| Jun 30, 2025 | 3.40 Mn |
| Jun 30, 2025 | 3.40 Mn |
| Mar 31, 2025 | 3.08 Mn |
| Mar 31, 2025 | 3.08 Mn |
| Dec 31, 2024 | 3.56 Mn |
| Dec 31, 2024 | 3.56 Mn |
| Sep 30, 2024 | 1.86 Mn |
| Sep 30, 2024 | 1.86 Mn |
| Jun 30, 2024 | 1.36 Mn |
| Jun 30, 2024 | 1.36 Mn |
| Mar 31, 2024 | 1.92 Mn |
| Mar 31, 2024 | 1.92 Mn |
| Dec 31, 2023 | 926,000.00 |
| Dec 31, 2023 | 926,000.00 |
| Sep 30, 2023 | 10.13 Mn |
| Sep 30, 2023 | 10.13 Mn |
| Jun 30, 2023 | 135,000.00 |
| Jun 30, 2023 | 135,000.00 |
| Mar 31, 2023 | 2.83 Mn |
| Mar 31, 2023 | 2.83 Mn |
| Dec 31, 2022 | 1.30 Mn |
| Dec 31, 2022 | 1.30 Mn |
| Jun 30, 2021 | 50,000.00 |
| Jun 30, 2021 | 50,000.00 |
| Sep 30, 2020 | 100,000.00 |
| Sep 30, 2020 | 100,000.00 |
| Jun 30, 2020 | 100,000.00 |
| Jun 30, 2020 | 100,000.00 |
| Mar 31, 2020 | 150,000.00 |
| Mar 31, 2020 | 150,000.00 |
| Dec 31, 2019 | 1.50 Mn |
| Dec 31, 2019 | 1.50 Mn |
| Sep 30, 2019 | 1.50 Mn |
| Sep 30, 2019 | 1.50 Mn |
| Jun 30, 2019 | 1.50 Mn |
| Jun 30, 2019 | 1.50 Mn |
| Mar 31, 2019 | 2.85 Mn |
| Mar 31, 2019 | 2.85 Mn |
| Dec 31, 2013 | 56,047.00 |
| Dec 31, 2013 | 56,047.00 |
| Sep 30, 2013 | 56,047.00 |
| Sep 30, 2013 | 56,047.00 |
| Jun 30, 2013 | 56,047.00 |
| Jun 30, 2013 | 56,047.00 |
| Mar 31, 2013 | 56,047.00 |
| Mar 31, 2013 | 56,047.00 |
| Dec 31, 2012 | 56,047.00 |
| Dec 31, 2012 | 56,047.00 |
| Sep 30, 2012 | 56,047.00 |
| Sep 30, 2012 | 56,047.00 |